Search research articles
Contact Us
Filters
Showing results (301-310 of 319) with videos related to
Page
of 32
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2014
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
D Schadendorf, M M Amonkar, M Milhem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
S Dugas-Breit, A Forschner, M Erdmann, et al.
ESMO Open
|
August 3, 2024
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
E Chatziioannou, L M Serna Higuita, S Kreft, et al.
The FEBS Journal
|
June 23, 2015
Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients
Fiona Lanigan, Gerard L Brien, Yue Fan, et al.
The British Journal of Dermatology
|
January 17, 2021
A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences
C Dessinioti, A C Geller, A Stergiopoulou, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 12, 2023
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study
J-M L'Orphelin, J Cassecuel, L Kandolf, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 25, 2024
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology
L Kandolf, P A Ascierto, L Bastholt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T Amaral, M Ottaviano, A Arance, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 319) with videos related to
Sort By:
Page
of 32
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2014
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
D Schadendorf, M M Amonkar, M Milhem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
S Dugas-Breit, A Forschner, M Erdmann, et al.
ESMO Open
|
August 3, 2024
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
E Chatziioannou, L M Serna Higuita, S Kreft, et al.
The FEBS Journal
|
June 23, 2015
Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients
Fiona Lanigan, Gerard L Brien, Yue Fan, et al.
The British Journal of Dermatology
|
January 17, 2021
A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences
C Dessinioti, A C Geller, A Stergiopoulou, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 12, 2023
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study
J-M L'Orphelin, J Cassecuel, L Kandolf, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 25, 2024
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology
L Kandolf, P A Ascierto, L Bastholt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T Amaral, M Ottaviano, A Arance, et al.
Page
of 32